ZyVersa Therapeutics, Inc. Stock News

Key Highlights: Second research site selected to enhance enrollment in the Phase 2a clinical trial for Cholesterol Efflux MediatorTM VAR 200 in patients with diabetic kidney disease planned to begin H

To learn more about ZyVersa's Inflammasome ASC Inhibitor and Renal Pipelines, schedule a one-on-one meeting on 2024 BIO International Conference's Portal.

NLRP1 & pyrin govern inflammation in Alzheimer's Disease, and release of inflammasome laden extracellular vesicles induces cardiovascular inflammation.

Atherosclerosis (AS) and its sequelae are the most common cause of death in diabetic patients and one of the reasons why diabetes has entered the top 10 causes of death worldwide. The published data s

Key Highlights: Cholesterol Efflux MediatorTM VAR 200 on target to begin Phase 2a clinical trial in patients with diabetic kidney disease H1-2024. Inflammasome ASC Inhibitor IC 100 preclinical program

Phase 2a trial is on track to begin in the first half of 2024. Cholesterol Efflux Mediator TM VAR 200 is in development to ameliorate renal lipid accumulation that damages the kidneys' filtration syst

Mr. Glover will talk about inflammasomes, and how they trigger development and spread of damaging inflammation, the culprit behind many deadly diseases.

WESTON, Fla., Feb. 29, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for th

In obesity, inflammasome activation in fat tissue triggers cell death and release of inflammatory cytokines & ASC Specks, spreading damaging inflammation.

Investing in penny stocks offers a unique opportunity for investors looking to expand their portfolios with potentially high-reward options. Recognized for their affordability, these stocks allow indi

ZyVersa Therapeutics (NASDAQ: ZVSA ) stock is rocketing higher on Monday alongside heavy pre-market trading of the clinical-stage biopharmaceutical company's shares. ZVA stock is seeing a lot of acti

Neurological diseases, which affect up to 16 million people over 18 years old in the US, are the leading cause of physical and cognitive disability. A growing body of evidence supports that activation

Inflammation resulting from activation of more than one type inflammasome and ASC specks contribute to development and progression of neurological disease

ZyVersa CEO will discuss development milestones for Cholesterol Efflux Mediator VAR 200 and Inflammasome ASC Inhibitor IC 100 at BIO CEO & Investor Conf.

NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications (e.g., Type 2 Diabetes, Hypertension, Heart Disease).